Scarica l'app Stockscreener
4.40
2.33%
0.10
Precedente Chiudi:
$4.30
Aprire:
$4.23
Volume 24 ore:
62,224
Relative Volume:
0.77
Capitalizzazione di mercato:
$35.11M
Reddito:
$442.00K
Utile/perdita netta:
$-30.46M
Rapporto P/E:
-7.2131
EPS:
-0.61
Flusso di cassa netto:
$-27.47M
1 W Prestazione:
-11.11%
1M Prestazione:
+7.58%
6M Prestazione:
-43.76%
1 anno Prestazione:
-57.28%
Intervallo 1D:
$4.23
$4.51
Intervallo di 1 settimana:
$4.04
$5.1245
Portata 52W:
$3.8181
$11.00
Clene Inc Stock (CLNN) Company Profile
Nome
Clene Inc
Settore
Industria
Telefono
801-676-9695
Indirizzo
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Confronta CLNN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
4.40 | 35.11M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
30.52 | 36.90B | 26.13B | 1.37B | 3.00B | 1.11 |
|
GIS
General Mills Inc
|
63.61 | 35.06B | 19.90B | 2.60B | 2.80B | 4.60 |
|
K
Kellanova Co
|
80.50 | 27.75B | 12.80B | 1.01B | 927.00M | 2.91 |
|
MKC
Mccormick Co Inc
|
78.86 | 21.16B | 6.68B | 792.60M | 774.40M | 2.94 |
|
HRL
Hormel Foods Corp
|
31.68 | 17.39B | 11.92B | 805.04M | 1.01B | 1.46 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-02 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-28 | Iniziato | Oppenheimer | Outperform |
Clene Inc Borsa (CLNN) Ultime notizie
Clene Secures $10M Debt Facility to Enhance Position - TipRanks
Clene Secures $10 Million Debt Facility to Advance ALS and Neurodegenerative Disease Treatments - Citybuzz
IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments - Yahoo Finance
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan - The Manila Times
Clene Inc. Provides Update on Corporate Presentation and ALS Clinical Trials - Defense World
IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway - Yahoo Finance
Clene Receives FDA Guidance on Accelerated Approval Path for ALS Treatment CNM-Au8 - Citybuzz
Clene Gains FDA Support for ALS Treatment Approval - TipRanks
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS - The Manila Times
FDA Opens Accelerated Approval Path for Clene's Breakthrough ALS Treatment After 78% Survival Benefit - StockTitan
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
Clene (NASDAQ:CLNN) Given New $84.00 Price Target at Benchmark - Defense World
Clene shares hold Buy rating as analyst sees FDA decision impacting time to market - Investing.com
Roth Capital Has Bearish Forecast for Clene FY2024 Earnings - Defense World
Clene (NASDAQ:CLNN) Price Target Lowered to $83.00 at Canaccord Genuity Group - Defense World
HC Wainwright Reaffirms Buy Rating for Clene (NASDAQ:CLNN) - Defense World
AWM Investment Company, Inc. Expands Stake in Clene Inc - GuruFocus.com
Clene price target lowered to $83 from $86 at Canaccord - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Clene Inc - GuruFocus.com
Certain Warrants of Clene Inc. are subject to a Lock-Up Agreement Ending on 15-NOV-2024. - Marketscreener.com
Clene Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Canaccord cuts Clene stock target, holds buy rating on FDA meeting - Investing.com UK
Clene Inc (CLNN) Q3 2024 Earnings: EPS of -$1.22 Beats Estimates, Revenue at $0.087 Million Misses Expectations - GuruFocus.com
Clene Inc. (CLNN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Clene Announces Q3 2024 Results and ALS Drug Progress - TipRanks
Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights - The Manila Times
(CLNN) Technical Data - Stock Traders Daily
Clene to Meet with FDA Leadership to Discuss CNM-Au8 Biomarker for ALS Treatment - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership - Yahoo Finance
Clene Unveils Phase 3 Trial Design at NEALS - TipRanks
Clene Showcases Progress on CNM-Au8 for Neurodegenerative Diseases at Investor Conferences - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences - Yahoo Finance
(CLNN) Trading Report - Stock Traders Daily
IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements - Yahoo Finance
Clene Secures $7.3M in Funding to Advance Neurodegenerative Disease Treatment - Vancity Buzz
Canaccord retains price target, buy rating on Clene shares post-webinar - Investing.com Canada
IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences - Yahoo Finance
Clene Inc. to Present at Two Upcoming Investor Conferences in October - Vancity Buzz
Clene to Present at Upcoming October Conferences - The Manila Times
Clene (NASDAQ: CLNN) Announces Participation At Two Upcoming Investor Conferences - Barchart
Clene (NASDAQ:CLNN) Price Target Cut to $86.00 by Analysts at Canaccord Genuity Group - Defense World
Independent Chairman of the Board of Clene Picks Up 26% More Stock - Simply Wall St
Independent Chairman of the Board of Clene David Matlin Buys 26% More Shares - Yahoo Finance
Canaccord cuts Clene stock price target, maintains Buy rating By Investing.com - Investing.com South Africa
Canaccord cuts Clene stock price target, maintains Buy rating - Investing.com
Clene Secures $7.3 Million in Funding Through Direct Offering and Private Placements - Vancity Buzz
IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M - Yahoo Finance
Clene Inc. director David Matlin buys $438k in company stock - Investing.com
Clene Inc Azioni (CLNN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Clene Inc Azioni (CLNN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
| Etherington Robert Dee | Chief Executive Officer |
Jul 29 '24 |
Option Exercise |
3.00 |
27,320 |
81,960 |
30,149 |
| General Resonance LLC | 10% Owner |
Apr 30 '24 |
Sale |
0.42 |
13,000 |
5,416 |
15,326,712 |
| General Resonance LLC | 10% Owner |
May 01 '24 |
Sale |
0.40 |
13,000 |
5,148 |
15,313,712 |
| General Resonance LLC | 10% Owner |
Apr 24 '24 |
Sale |
0.33 |
10,000 |
3,278 |
15,349,712 |
| General Resonance LLC | 10% Owner |
Apr 09 '24 |
Sale |
0.39 |
22,500 |
8,674 |
15,428,212 |
2.20%
0.84%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):